Technical Analysis for FOLD - Amicus Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 12.25 -2.62% -0.33
FOLD closed down 2.62 percent on Friday, May 17, 2019, on 67 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Down Down
See historical FOLD trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.62%
Lower Bollinger Band Walk Weakness -2.62%
Up 3 Days in a Row Strength -2.62%
Oversold Stochastic Weakness -2.62%
200 DMA Support Bullish -2.31%
Stochastic Buy Signal Bullish -2.31%
Lower Bollinger Band Walk Weakness -2.31%

Older signals for FOLD ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.
Medicine Biopharmaceutical Rare Diseases Inborn Errors Of Metabolism Orphan Drugs Enzyme Replacement Therapy Pompe Disease Fabry Disease Gaucher Disease Lipid Storage Disorders Lysosomal Storage Disorders Protein Folding Treatment Of Pompe Disease
Is FOLD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.62
52 Week Low 8.27
Average Volume 2,846,670
200-Day Moving Average 12.2212
50-Day Moving Average 13.4088
20-Day Moving Average 13.1055
10-Day Moving Average 12.854
Average True Range 0.5709
ADX 18.25
+DI 15.7457
-DI 24.3443
Chandelier Exit (Long, 3 ATRs ) 12.5773
Chandelier Exit (Short, 3 ATRs ) 13.7327
Upper Bollinger Band 14.2254
Lower Bollinger Band 11.9856
Percent B (%b) 0.12
BandWidth 17.090535
MACD Line -0.2705
MACD Signal Line -0.1457
MACD Histogram -0.1248
Fundamentals Value
Market Cap 2.02 Billion
Num Shares 165 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -8.33
Price-to-Sales 135.92
Price-to-Book 7.22
PEG Ratio -0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.99
Resistance 3 (R3) 13.05 12.88 12.86
Resistance 2 (R2) 12.88 12.69 12.84 12.82
Resistance 1 (R1) 12.56 12.57 12.48 12.50 12.78
Pivot Point 12.39 12.39 12.34 12.35 12.39
Support 1 (S1) 12.07 12.20 11.99 12.01 11.72
Support 2 (S2) 11.90 12.08 11.86 11.68
Support 3 (S3) 11.58 11.90 11.64
Support 4 (S4) 11.52